Some 6 analysts have recommended on the stock of Novocure Ltd. (NASDAQ:NVCR) so far and from them the equity has an average call of Buy. But what does that indicate? It deciphers analysts? recommendations; shareholders should know that 1.00 ? 1.24 implies that a stock is a BUY. Call of 1.75 – 2.24 implies that an equity is a HOLD. SELL recommendation is represented by numbers 2.75 – 3.00.
Let’s look into the technical of the stock
The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions. Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend. The market is in highly overbought territory. Beware of a trend reversal.
As for the price, analysts project that shares of Novocure Ltd. will be trading around $19.33 in the next 12 months.
The stock price is influenced by the financial performance and represents investors opinion of its future. That being the case, shareholders should recall that Novocure Ltd. posted EPS of $(0.21) in its recent quarter.
The firm recorded the EPS from sales of 34.88M%, which increased 0.63%% from a same period a year ago. Compared to the previous period, the revenue growth jumped/decreased by grow%.
Novocure Ltd. incurred expenses totaling $11.66M to produce the revenue. Gross profit, which is computed by deducting cost of sales from sales, was $23.22M.
Analysts on the average are projecting Novocure Ltd. to post EPS of $-0.18 in the ongoing quarter.
Does Novocure Ltd. have the capacity to surpass expectations? Casting an eye on the firm’s liquidity position, you note that the firm generated net cash of $(26.91M) from its operations in the previous quarter, resulting in free cash flow of $(29.34M). Net change in cash came at $(15.19M).
Furthermore, the firm’s asset position was $264.63M at the close of the latest quarter. But Novocure Ltd. is carrying liabilities totaling $135.73M.
The firm ended the latest quarter with diluted due shares of 87.45M.
Novocure(TM) (NASDAQ:NVCR) announced today that the first patient has been enrolled in the RTOG Foundation’s phase 2 pilot trial testing Optune together with bevacizumab for patients with bevacizumab-refractory recurrent glioblastoma (GBM).